Zekun Zhou

Zekun Zhou

Auto-generated profile, based on publicly available information

Zekun Zhou

Hunan Key Laboratory of Oral Health Research & Hunan 3D Printing Engineering Research Center of Oral Care & Hunan Clinical Research Center of Oral Major Diseases and Oral Health & Academician Workstation for Oral-maxilofacial and Regenerative Medicine & Xiangya Stomatological Hospital & Xiangya School of Stomatology, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in International Journal of Oral Science
Verified
Journal Article
Open access
PDF file
Jianfei TangJianfei Tang
Jianfei Tang
JLJunjie Liu
Junjie Liu
ZZZekun Zhou
Zekun Zhou
XCXinyan Cui
Xinyan Cui
HTHua Tu
Hua Tu
OLOu-Sheng Liu
Ou-Sheng Liu
Oral submucous fibrosis (OSF), characterized by excessive deposition of extracellular matrix (ECM) that causes oral mucosal tissue sclerosis, and even cancer transformation, is a chronic, progressive fibrosis disease. However, despite some advancements in recent years, no targeted antifibrotic strategies for OSF have been approved; likely because the complicated mechanisms that initiate and drive fibrosis remain to be determined. In this review, we briefly introduce the epidemiology and etiology of OSF. Then, we highlight how cell-intrinsic changes in significant structural cells can drive fibrotic response by regulating biological behaviors, secretion function, and activation of ECM-producing myofibroblasts. In addition, we also discuss the role of innate and adaptive immune cells and how they contribute to the pathogenesis of OSF. Finally, we summarize strategies to interrupt key mechanisms that cause OSF, including modulation of the ECM, inhibition of inflammation, improvement of vascular disturbance. This review will provide potential routes for developing novel anti-OSF therapeutics.

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
ZZZekun Zhou
Zekun Zhou
FYFei Yan
Fei Yan
OLOu-Sheng Liu
Ou-Sheng Liu
Interleukin (IL)‐33, a member of the IL‐1 superfamily, functions as an alarm signal, which is released upon cell injury or tissue damage to alert the immune system. It has emerged as a chief orchestrator in immunity and has a broad pleiotropic action that influences differentiation, maintenance and function of various immune cell types via the ST2 receptor. Although it has been strongly associated with immunopathology, critically, IL‐33 is involved in host defence, tissue repair and homeostasis. In this review, we provide an overview of the signalling pathway of IL‐33 and highlight its regulatory functions in immune cells. Furthermore, we attempt a broader discussion of the emerging functions of IL‐33 in host defence, tissue repair, metabolism, inflammatory disease and cancer, suggesting potential avenues to manoeuvre IL‐33/ST2 signalling as treatment options.

28 June 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JGJianyu Gu
Jianyu Gu
ZZZekun Zhou
Zekun Zhou
SXShihan Xu
Shihan Xu
WPWen Pan
Wen Pan
JWJinsong Wang
Jinsong Wang
JXJunji Xu
Junji Xu